The drug treatments that can be used in the middle stage of hepatocellular carcinoma include targeted drugs such as sorafenib and PD1-related immunotherapy such as tirilizumab. The drugs for hepatocellular carcinoma are mainly divided into targeted drugs and immunotherapy. 1. Targeted drugs: such as sorafenib, apatinib, lenvatinib and so on. For example, Apatinib is a small molecule vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase inhibitor, which can inhibit tumor angiogenesis and tumor growth. 2. Immunotherapy: PD-1 inhibitors are the latest immunotherapy drugs, commonly used drugs are PD-1 (programmed death receptor 1) inhibitors, such as karelizumab, tirilizumab and other drugs. Some studies claim that the 1-year overall survival rate of patients with inoperable advanced hepatocellular carcinoma treated with carelizumab monotherapy is about 56%. Usually, the above drugs are combined with local therapeutic surgeries (intervention, ablation, etc.), targeted therapeutic agents or chemotherapy, etc., and some patients can also be treated with single drug. It is recommended that liver cancer patients should go to regular hospitals to evaluate their conditions and actively cooperate with the treatment as prescribed by doctors in order to improve the quality of life and prolong the survival period. Drug treatment should be carried out under professional doctor’s guidance, do not use drugs on your own.